Alendronate sodium hydrate - CAS 121268-17-5
Not Intended for Therapeutic Use. For research use only.
Product Name:
Alendronate sodium hydrate
Catalog Number:
G-704650, MK-217
CAS Number:
Alendronate, a nitrogen-containing bisphosphonate, is a potent inhibitor of bone resorption used for the treatment and prevention of osteoporosis.
Molecular Weight:
Molecular Formula:
Chemical Structure
CAS 121268-17-5 Alendronate sodium hydrate

Related Products

CAS 22232-54-8 Carbimazole

(CAS: 22232-54-8)

Carbimazole is used to treat hyperthyroidism. Carbimazole is a pro-drug as after absorption it is converted to the active form, methimazole. Methimazole prevent...

CAS 23642-66-2 Benfluorex hydrochloride

Benfluorex hydrochloride
(CAS: 23642-66-2)

Benfluorex hydrochloride is a known hypolipidaemic agent with possible glucose-lowering effects. Several clinical studies have shown a reduction in triglyceride...

CAS 4205-90-7 Clonidine

(CAS: 4205-90-7)

Clonidine is an α2-Adrenergic agonist for neuropathic pain.

CAS 50-33-9 Phenylbutazone

(CAS: 50-33-9)

Phenylbutazone is used as a non-steroidal anti-inflammatory agent for the treatment of chronic pain, including the symptoms of arthritis. In the United States a...

CAS 61281-38-7 Schisandrin A

Schisandrin A
(CAS: 61281-38-7)

Schizandrin A is extracted from the seeds of Schisandra chinensis (Turcz.) Baill that is reported to have liver-protective, antitumor, and antioxidant activitie...

CAS 406-76-8 DL-Carnitine

(CAS: 406-76-8)

Carnitine regulates fatty acid transport in mitochondria, elevates serum carnitine fractions.

CAS 631-01-6 Quillaic acid

Quillaic acid
(CAS: 631-01-6)

Quillaic acid is the major aglycone of the widely studied saponins of the Chilean indigenous tree Quillaja saponaria Mol and can elicit dose-dependent antinocic...

CAS 138926-19-9 Ibandronate sodium

Ibandronate sodium
(CAS: 138926-19-9)

Ibandronate (< 100 μM) inhibits growth of both prostate cancer cell lines (LNCaP and PC-3) in a dose dependent manner.

CGP-15720 hydrochloride
(CAS: 76692-12-1)

CGP-15720 is a antitumor agent

CHF 1255
(CAS: 146728-52-1)

CHF 1255, a tetrahydronaphthalen derivative, has been found to be probably effective against heart failure.

CAS 155294-62-5 NB-598 Maleate

NB-598 Maleate
(CAS: 155294-62-5)

SE inhibitor NB-598 significantly inhibited both basal and glucose-stimulated insulin secretion from mouse pancreatic islets. CaV channels were markedly inhibit...

CAS 123-99-9 1,7-Heptanedicarboxylic Acid

1,7-Heptanedicarboxylic Acid
(CAS: 123-99-9)

Azelaic acid, produced by ozone cracking of unsaturated fatty acid, could be commonly used in grease, cosmetics and pharmaceuticals.

CAS 15299-99-7 Napropamid

(CAS: 15299-99-7)

Napropamid is a selective systemic amide herbicide which is used against a number of annual grasses and broad-leaved weeds for inhibiting root development and g...

BMS-214662 mesylate
(CAS: 474010-58-7)

BMS-214662 mesylate is a potent and selective inhibitor of farnesyltransferase that induces mitochondrial apoptosis in chronic myeloid leukemia stem/progenitor ...

PD 130908
(CAS: 131505-02-7)

PD 130908 is an effective hypoxic cytotoxin as an analogue of RSU 1069, but less potent than the hypoxic cell radiosensitizer RSU 1069. Toxicity toward hypoxic ...

CAS 221174-33-0 Glyoxalase I inhibitor

Glyoxalase I inhibitor
(CAS: 221174-33-0)

Glyoxalase I inhibitor is a potent Glyoxalase I inhibitor, candidate for anticancer agents.

CAS 78214-33-2 Ginsenoside Rh2

Ginsenoside Rh2
(CAS: 78214-33-2)

Ginsenoside Rh2 is a bioactive metabolite of the ginsenoside component of Panax ginseng. It is a potent anti-inflammatory and anticancer drug and exhibits antib...

Aluminum phthalocyanine tetrasulfonate t
(CAS: 118887-28-8)

Aluminum phthalocyanine disulfonate is a mixture of regional isomers, in which sulfonate group can be in 3- or 4- position of phenyl ring. It is a potent photos...

(CAS: 14760-71-5)

MK785, an imidazol derivative, has been found to inhibit the formation of aortic histamine through influencing the aortic histidine decarboxylase at some extent...

CAS 117-10-2 1,8-Dihydroxyanthraquinone

(CAS: 117-10-2)

1,8-Dihydroxyanthraquinone, an anthraquinone derivative, could be widely used as antioxidant, dye intermediate and a raw material to synthesise sorts of product...

Reference Reading

1.[Minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Chatani Y1. Clin Calcium. 2005 Jan;15(1):9-14.
Minodronic acid hydrate is one of the new-generation bisphosphonates containing nitrogen. The drug has an inhibitory effect on bone resorption by suppressing the osteoclastic function. Minodronic acid hydrate is being developed as a therapeutic drug of osteoporosis. In non-clinical study, the inhibitory effect of minodronic acid hydrate on the decrease in the bone mineral density and on the reduction in the bone intensity in ovariectomized rat osteoporosis models. The results of the clinical studies conducted so far showed that minodronic acid hydrate administered once daily for 36 weeks increases the bone mineral density of lumbar spine (L2-4BMD) significantly compared to the placebo group. It was speculated that minodronic acid hydrate has an increasing effect on the bone mineral density that is at least equivalent to that of alendronate and risedronate. It was also expected that the incidence of digestive diseases with minodronic acid hydrate is lower than that with the existing bisphosphonates.
2.[Pharmacological and clinical properties of alendronate sodium hydrate].
Ohta T1, Komatsu S, Tokutake N. Nihon Yakurigaku Zasshi. 2002 Dec;120(6):409-19.
Alendronate (alendronate sodium hydrate; Bonalon Tablet, 5 mg) is a nitrogen-containing bisphosphonate, which combines with the bone surface and reduces osteoclast-mediated bone resorption. It is a third-generation bisphosphonate compound, specifically distributed on the surface of bone resorption and taken into osteoclasts. Under the closed circumstances which is formed with osteoclast and the bone surface, alendronate becomes detached from the bone surface and taken into osteoclast since acid released from osteoclast leads to pH decrease (acidified). The uptaken alendronate blocks the pathway of mevalonic acid synthesis, which is cholesteric synthesis, inhibits the prenylation of GTP binding protein, and decreases the osteoclast's function by influencing the cytoskeleton. This restraint of alendronate in bone resorption against osteoclasts is reversible, showing no cytotoxicity at more than hundredfold concentration level at which action occurs.
3.Glucocorticoid Steroid and Alendronate Treatment Alleviates Dystrophic Phenotype with Enhanced Functional Glycosylation of α-Dystroglycan in Mouse Model of Limb-Girdle Muscular Dystrophy with FKRPP448L Mutation.
Wu B1, Shah SN2, Lu P2, Milazi S2, Bollinger LE2, Blaeser A2, Madden KL2, Sun Y3, Luckie TM2, Cox MD3, Sparks S4, Harper AD4, Lu QL5. Am J Pathol. 2016 Apr 21. pii: S0002-9440(16)30059-1. doi: 10.1016/j.ajpath.2016.02.015. [Epub ahead of print]
Fukutin-related protein-muscular dystrophy is characterized by defects in glycosylation of α-dystroglycan with variable clinical phenotypes, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard treatment for Duchenne and other muscular dystrophies with serious adverse effects, including excessive weight gain, immune suppression, and bone loss. Bisphosphonates have been used to treat Duchenne muscular dystrophy for prevention of osteoporosis. Herein, we evaluated prednisolone and alendronate for their therapeutic potential in the FKRPP448L-mutant mouse representing moderate limb-girdle muscular dystrophy 2I. Mice were treated with prednisolone, alendronate, and both in combination for up to 6 months. Prednisolone improved muscle pathology with significant reduction in muscle degeneration, but had no effect on serum creatine kinase levels and muscle strength.